Semaglutide and NT-proBNP in Obesity-Related HFpEF
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“Semaglutide and NT-proBNP in Obesity-Related HFpEF”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/
Topics
Semaglutide · Natriuretic peptides · Obesity-related HFpEF · Heart failure with preserved ejection fraction · GLP-1 receptor agonist · Obesity · Body weight reduction · STEP-HFpEF trial · STEP-HFpEF DM trial · Type 2 diabetes · KCCQ Clinical Summary Score · health status · Randomized controlled trial · Double-blind randomized controlled trial · Secondary analysis · Natriuretic peptides · Mechanical unloading · HF pathobiology · Biomarker stratification · Secondary analysis · Cardiac wall stress · Weight management · Heart failure symptoms · Functional impairment · Dual primary endpoints · Tertile analysis · Cardiometabolic disease · GLP-1 receptor agonism in heart failure · Obesity-related HFpEF · Biomarker-guided treatment response
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459